RMP
VYGR icon

Richards, Merrill & Peterson’s Voyager Therapeutics VYGR Stock Holding History

Richards, Merrill & Peterson’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30
Closed -$170 – 530
2024
Q4 		$170 Buy
+30
New +$193 ﹤0.01% 493

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Richards, Merrill & Peterson's VYGR Position: Q1 2025 in Review

Richards, Merrill & Peterson sold out of Voyager Therapeutics (VYGR) in Q1 2025, closing a stake of 30 shares — an estimated $170 sold.

Richards, Merrill & Peterson first reported a position in VYGR in Q4 2024 and held it in 1 quarter. The position peaked at $170 in Q4 2024. 116 funds tracked by Wall St. Rank hold VYGR as of Q1 2025.

  • Richards, Merrill & Peterson reported no remaining Voyager Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 30 Voyager Therapeutics shares in Q1 2025, an estimated $170.
  • Richards, Merrill & Peterson first reported a position in Voyager Therapeutics in Q4 2024 and held it in 1 quarter.
  • Richards, Merrill & Peterson's Voyager Therapeutics position peaked at $170 in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q1 2025, filed 7 May 2025.